Table 4.
Effect of Bevacizumab Added to Carboplatin and Paclitaxel Chemotherapy on Hazard Ratios for Overall Survival for all Adults with Stage IIIB/IV, Non-squamous NSCLC for Patients Diagnosed from 2005–2009.
| Re-estimated Propensity Score Using Exclusion Criteria Noted in Sander et al.6
| |
|---|---|
| Models | Hazard Ratio (95% CI)
|
| Bevacizumab Carboplatin-Paclitaxel- vs Carboplatin-Paclitaxel 2005–2010 | |
| Multivariable-adjusted modela,b | 0.80 (0.66–0.98) |
| Propensity score-adjusted modela,c | 0.82 (0.68–0.99) |
| Weighting (stabilized IPW) a, d | 0.76 (0.55–1.05) |
| Matching 1:1e | 0.63 (0.45–0.89) |
Sample sizes: BCP vs CP 2005–2010 = 198 and 911.
The model was adjusted for age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, American Joint Commission on Cancer (AJCC) stage, and diagnoses noted in the Sandler exclusion criteria that are noted in Table 2.
The propensity of receiving BCP was estimated using a multivariable logistic regression model that included age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage and diagnoses noted in the Sandler exclusion criteria noted in Table 2. The propensity score was then added as a predictor in the survival model.
The propensity score was used to create stabilized weights
Sample sizes: BCP vs CP 2005–2010 = 193 and 193, BCP and CP patients were matched based on their propensity score.